Results 21 to 30 of about 22,370 (168)

Inflammation and Incretins

Indian Journal of Endocrinology and Metabolism, 2012
Nutrient excess results in systemic inflammation in diabetes contributing to insulin resistance, dyslipidaemia and increased cardiovascular risk. GLP-1 agonists and DPP-4 inhibitors, which are now well accepted therapies for diabetes may play a unique role in modulating this inflammatory process.
openaire   +3 more sources

Update on incretin hormones [PDF]

Annals of the New York Academy of Sciences, 2011
The incretin hormones glucagon‐like‐peptide‐1 (GLP‐1) and glucose‐dependent insulinotropic polypeptide (GIP) are released from the intestine following oral ingestion of nutrients. Incretins promote insulin secretion, while GLP‐1 also inhibits glucagon release and gastric emptying, minimizing postprandial glucose excursions.
Phillips, Liza K., Prins, Johannes B.
openaire   +5 more sources

Why Are Incretin-Based Therapies More Efficient in East Asians? Perspectives from the Pathophysiology of Type 2 Diabetes and East Asian Dietary Habits [PDF]

European Medical Journal Diabetes, 2015
Type 2 diabetes mellitus (T2D) is one of the most serious global health problems. This is partly a result of its drastic increase in East Asia, which now comprises more than a quarter of the global diabetes population. Ethnicity and lifestyle factors are
Daisuke Yabe, Hitoshi Kuwata, Masahiro Iwasaki, Yutaka Seino   +3 more
doaj  

Role of Incretin Axis in Inflammatory Bowel Disease

Frontiers in Immunology, 2017
The inflammatory bowel diseases (IBDs), including Crohn’s disease (CD) and ulcerative colitis (UC), are chronic inflammatory conditions of the gastrointestinal tract and involve a complicated reciprocity of environmental, genetic, and immunologic factors.
Lihua Duan, Xiaoquan Rao, Zachary Braunstein, Amelia C. Toomey, Jixin Zhong   +4 more
doaj   +1 more source

Bidirectional Interactions Between the Gut Microbiota and Incretin-Based Therapies

Life
Obesity, insulin resistance, type 2 diabetes mellitus (T2DM) and metabolic syndrome have been largely correlated to a reduction in bacterial load and diversity, resulting in a condition known as intestinal dysbiosis.
Vincenzo Trapanese, Annamaria Dagostino, Maria Resilde Natale, Federica Giofrè, Clara Vatalaro, Melania Melina, Francesca Cosentino, Silvia Sergi, Felice Imoletti, Rocco Spagnuolo, Franco Arturi   +10 more
doaj   +1 more source

Relevance of Autophagy Induction by Gastrointestinal Hormones: Focus on the Incretin-Based Drug Target and Glucagon

Frontiers in Pharmacology, 2019
The biology of autophagy in health and disease conditions has been intensively analyzed for decades. Several potential interventions can induce autophagy in preclinical research; however, none of these interventions are ready for translation to clinical ...
Keizo Kanasaki, Keizo Kanasaki, Emi Kawakita, Daisuke Koya, Daisuke Koya   +4 more
doaj   +1 more source

AMPK is involved in the regulation of incretin receptors expression in pancreatic islets under a low glucose concentration. [PDF]

PLoS ONE, 2013
The precise role of AMP-activated protein kinase (AMPK), a target of metformin, in pancreatic β cells remains controversial, even though metformin was recently shown to enhance the expression of incretin receptors (GLP-1 and GIP receptors) in pancreatic ...
Kazuki Tajima, Jun Shirakawa, Yu Togashi, Hideaki Inoue, Koichiro Sato, Kazuki Orime, Yuzuru Ito, Mitsuyo Kaji, Eri Sakamoto, Akinobu Nakamura, Kazutaka Aoki, Yoshio Goshima, Tatsuya Atsumi, Yasuo Terauchi   +13 more
doaj   +1 more source

Variation in responses to incretin therapy: Modifiable and non-modifiable factors

Frontiers in Molecular Biosciences, 2023
Type 2 diabetes (T2D) and obesity have reached epidemic proportions. Incretin therapy is the second line of treatment for T2D, improving both blood glucose regulation and weight loss.
Gregory O. Austin, Alejandra Tomas
doaj   +1 more source

Glucagon Like Peptide 1 and Evidence Around Diabetes Specific Nutrition

World Nutrition, 2019
There has been significant research and development in pharmaco-therapeutic molecules for management of type 2 diabetes mellitus (T2DM). Diabetes specific nutrition intervention & newer incretin-based therapies have gained a lot of attention.
ANSHU JOSHI, SAMEER RAO, GANESH KADHE
doaj   +1 more source

GLUT2 and the incretin receptors are involved in glucose-induced incretin secretion [PDF]

Molecular and Cellular Endocrinology, 2007
Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are incretins secreted in response to oral glucose ingestion by intestinal L and K cells, respectively. The molecular mechanisms responsible for intestinal cell glucose sensing are unknown but could be related to those described for beta-cells, brain and hepatoportal
Cani, P.D., Holst, J.J., Drucker, D.J., Delzenne, N.M., Thorens, B., Burcelin, R., Knauf, C.   +6 more
openaire   +4 more sources